Ryder System, Inc. (R)

Verve Therapeutics Stock Forecast

Stock Price Forecast

The 8 analysts that cover Verve Therapeutics stock have a consensus rating of "Buy" and an average price target of $185.38, which forecasts a 5.67% increase in the stock price over the next year. The lowest target is $150 and the highest is $215.

Price Target: $185.38 (+5.67%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$150	$185.38	$190	$215
Change	-14.50%	+5.67%	+8.30%	+22.55%

Analyst Ratings

The average analyst rating for Verve Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	2	2	2	2	2	1
Buy	2	2	2	2	3	5
Hold	3	3	2	2	2	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	7	7	6	6	7	9

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Daniel Imbro Stephens & Co.	Stephens & Co.	Hold Maintains $150 → $190	Hold	Maintains	$150 → $190	+8.30%	Jul 29, 2025
Daniel Moore Baird	Baird	Buy Maintains $186 → $192	Buy	Maintains	$186 → $192	+9.44%	Jul 28, 2025
Christyne McGarvey Morgan Stanley	Morgan Stanley	Buy Maintains $175 → $190	Buy	Maintains	$175 → $190	+8.30%	Jul 28, 2025
Matthew Harrison Susquehanna	Susquehanna	Buy Initiates $215	Buy	Initiates	$215	+22.55%	Jul 15, 2025
Brian Ossenbeck JP Morgan	JP Morgan	Hold Maintains $165 → $173	Hold	Maintains	$165 → $173	-1.39%	Jul 8, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

12.77B

Increased by 1.08%

from 12.64B

Revenue Next Year

13.33B

Increased by 4.35%

from 12.77B

EPS This Year

13.13

Increased by 18.74%

from 11.05

EPS Next Year

15.04

Increased by 14.57%

from 13.13

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	8.42B	9.66B	12.01B	11.78B	12.64B	12.77B	13.33B	14.68B
Revenue Growth	-5.67%	14.76%	24.30%	-1.90%	7.24%	1.08%	4.35%	10.14%
EPS	-2.35	9.64	17.04	8.73	11.05	13.13	15.04	17.65
EPS Growth	-	-	76.67%	-48.74%	26.58%	18.74%	14.57%	17.37%
Forward PE	-	-	-	-	-	13.37	11.67	9.94
No. Analysts	-	-	-	-	-	11	11	7

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	13.6B	14.4B	16.1B
Avg	12.8B	13.3B	14.7B
Low	10.2B	10.6B	13.1B

Revenue Growth

Revenue Growth	2025	2026	2027
High	7.8%	13.1%	20.6%
Avg	1.1%	4.3%	10.1%
Low	-19.4%	-17.3%	-1.7%

EPS Forecast

EPS	2025	2026	2027
High	14.03	17.43	19.45
Avg	13.13	15.04	17.65
Low	11.76	12.40	15.29

EPS Growth

EPS Growth	2025	2026	2027
High	26.9%	32.8%	29.3%
Avg	18.7%	14.6%	17.4%
Low	6.4%	-5.6%	1.7%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.